Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icotinib vs Chemotherapy as Adjuvant Therapy in EGFR-mutated NSCLC
NCT02448797Phase 3Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of icotinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
icotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02448797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448797.